Nkarta, Inc. Share Price & Technical Analysis
NKTX · $2.76 (+12.20%)
Healthcare / Biotechnology
$2.76
+12.20%
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myop…
Price chart
Seasonality
Jun has 0 positive and 5 negative years (last 5 years shown)
-12% return in Jun, -24% avg return in past 3 year Jun month.
54% return in 2026, 7% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 16% | 23% | -19% | 33% | 14% | -12% | – | – | – | – | – | – | 54% |
| 25 | -8% | -18% | 0% | 17% | -19% | -6% | 29% | -5% | -5% | 0% | -10% | 0% | -23% |
| 24 | 41% | 32% | -14% | -42% | 1% | -13% | 8% | -20% | -15% | -31% | -6% | -11% | -70% |
| 23 | -13% | -22% | -17% | 40% | -8% | -52% | 5% | -26% | -18% | 43% | 30% | 154% | 115% |
| 22 | -36% | -8% | 27% | 64% | -23% | -15% | 8% | 7% | -8% | -7% | -33% | -28% | -51% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$186.38M
P/E ratio
—
52W high
$3.65
52W low
$1.63
Volume
11,74,406
Beta
0.90
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Nkarta, Inc. share price today?
- Nkarta, Inc. (NKTX) last traded around $2.76 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NKTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NKTX. Download the app for real-time alerts.
- How can I analyze Nkarta, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.